Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity
| Autor: | W. Dorndorf, Patrick Oschmann, C. Schiel, Erwin Stolz, J. Kraus, Britta Engelhardt, A. Kern, A. Traupe, R. Bauer |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
biology business.industry CD3 Multiple sclerosis CD14 Cell General Medicine medicine.disease Central nervous system disease Cerebrospinal fluid Immune system Endocrinology medicine.anatomical_structure Neurology Methylprednisolone Internal medicine Immunology medicine biology.protein Neurology (clinical) business medicine.drug |
| Zdroj: | Acta Neurologica Scandinavica. 101:135-139 |
| ISSN: | 0001-6314 |
| Popis: | Objective - The expression of intercellular adhesion molecule-3 (ICAM-3), a member of the Ig supergene family, is restricted to immune competent cells. Expression of soluble and cell surface ICAM-3 (s- and c-ICAM-3) is preferentially seen in the state of low activation of the immune system. We studied the relevance of the expression levels of sand c-ICAM-3 in cerebrospinal fluid (CSF) and blood as markers for disease activity as well as the influence of high-dose methylprednisolone (MP) treatment upon the expression of s- and c-ICAM-3 in blood of patients with multiple sclerosis (MS). Materials and methods - A total of 33 patients (relapses n = 25, remission n = 8) with relapsing-remitting MS were included into the study. CSF and blood were acquired from all of them. Of the patients 24 were treated with high-dose MP. In those, blood was additionally collected at the 10th day of the therapy and after 3 months. Expression of c-ICAM-3 was determined by two colour FACS analysis, whereas the concentration levels of s-ICAM-3 were measured by ELISA, Results - In CSF we detected a significant decrease of the expression levels of c-ICAM-3 on CD3 + T cells in 25 patients suffering from an acute relapse in contrast to 8 patients with remission (P=0.04). In comparison to the levels before treatment and after 3 months, at the 10th day of MP treatment we obtained highly significant changes of the expression values of c-ICAM-3 both on CD3 + T cells (P=0.0004; P=0.005) and CD14 + monocytes/macrophages (P=0.0006; P=0.008) on the 10th day of high-dose MP treatment from 24 MS patients. Conclusion - The increase of ICAM-3 levels might indicate the antiinflammatory effect of the MP treatment. It could be interesting to search for similar effects investigating the new immune modulatoring therapy forms of MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|